131 related articles for article (PubMed ID: 16455512)
1. [Treatment of multiple myeloma].
Terriou L; Leleu X; Yakoub-Agha I
Bull Cancer; 2006 Jan; 93(1):101-6. PubMed ID: 16455512
[TBL] [Abstract][Full Text] [Related]
2. Treatment of multiple myeloma: 2009 update.
Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
[TBL] [Abstract][Full Text] [Related]
3. Treatment of multiple myeloma: an emphasis on new developments.
Kyle RA; Vincent Rajkumar S
Ann Med; 2006; 38(2):111-5. PubMed ID: 16581696
[TBL] [Abstract][Full Text] [Related]
4. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.
Vogl DT; Liu SV; Chong EA; Luger SM; Porter DL; Schuster SJ; Tsai DE; Perl A; Loren AW; Goldstein SC; Nasta SD; Andreadis C; Mangan PA; Hummel K; Siegel DL; Glatstein E; Stadtmauer EA
Am J Hematol; 2007 Dec; 82(12):1071-5. PubMed ID: 17696204
[TBL] [Abstract][Full Text] [Related]
5. Lenalidomide in multiple myeloma.
Richardson PG; Mitsiades C; Hideshima T; Anderson KC
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1165-73. PubMed ID: 16925483
[TBL] [Abstract][Full Text] [Related]
6. Melphalan and dexamethasone for patients with multiple myeloma who are not candidates for autologous stem cell transplantation.
Sharma A; Lokeshwar N; Raina V; Mohanti BK; Kumar R
Natl Med J India; 2007; 20(3):121-4. PubMed ID: 17867615
[TBL] [Abstract][Full Text] [Related]
7. High complete remission rate and durable remissions achieved with rational use of autologous stem-cell transplantation, thalidomide maintenance, and non-myeloablative allogeneic transplantation in patients with multiple myeloma.
Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
Clin Transplant; 2009; 23(6):839-47. PubMed ID: 20447186
[TBL] [Abstract][Full Text] [Related]
8. Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration.
Cibeira MT; Rosiñol L; Ramiro L; Esteve J; Torrebadell M; Bladé J
Eur J Haematol; 2006 Dec; 77(6):486-92. PubMed ID: 16978238
[TBL] [Abstract][Full Text] [Related]
9. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure.
Spencer A; Prince HM; Roberts AW; Prosser IW; Bradstock KF; Coyle L; Gill DS; Horvath N; Reynolds J; Kennedy N
J Clin Oncol; 2009 Apr; 27(11):1788-93. PubMed ID: 19273705
[TBL] [Abstract][Full Text] [Related]
10. Maintenance thalidomide following single cycle autologous peripheral blood stem cell transplant in patients with multiple myeloma.
Sahebi F; Spielberger R; Kogut NM; Fung H; Falk PM; Parker P; Krishnan A; Rodriguez R; Nakamura R; Nademanee A; Popplewell L; Frankel P; Ruel C; Tin R; Ilieva P; Forman SJ; Somlo G
Bone Marrow Transplant; 2006 May; 37(9):825-9. PubMed ID: 16565743
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation.
Biagi JJ; Mileshkin L; Grigg AP; Westerman DW; Prince HM
Bone Marrow Transplant; 2001 Dec; 28(12):1145-50. PubMed ID: 11803357
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma.
Raje N; Hideshima T; Anderson KC
Expert Rev Anticancer Ther; 2006 Sep; 6(9):1239-47. PubMed ID: 17020458
[TBL] [Abstract][Full Text] [Related]
13. Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy.
Palumbo A; Bringhen S; Falco P; Cavallo F; Ambrosini MT; Avonto I; Gay F; Caravita T; Bruno B; Boccadoro M
Cancer; 2007 Aug; 110(4):824-9. PubMed ID: 17594696
[TBL] [Abstract][Full Text] [Related]
14. New developments in the treatment of patients with multiple myeloma.
Minnema MC; van der Spek E; van de Donk NW; Lokhorst HM
Neth J Med; 2010 Jan; 68(1):24-32. PubMed ID: 20103818
[TBL] [Abstract][Full Text] [Related]
15. [New treatment strategy of multiple myeloma for cure].
Murakami H; Handa H
Gan To Kagaku Ryoho; 2006 Apr; 33(4):417-23. PubMed ID: 16612147
[TBL] [Abstract][Full Text] [Related]
16. Advances in therapy of multiple myeloma.
Bladé J; Rosiñol L
Curr Opin Oncol; 2008 Nov; 20(6):697-704. PubMed ID: 18841053
[TBL] [Abstract][Full Text] [Related]
17. Transplantation as salvage therapy for high-risk patients with myeloma in relapse.
Lee CK; Barlogie B; Zangari M; Fassas A; Anaissie E; Morris C; Van Rhee F; Cottler-Fox M; Thertulien R; Muwalla F; Mazher S; Badros A; Tricot G
Bone Marrow Transplant; 2002 Dec; 30(12):873-8. PubMed ID: 12476279
[TBL] [Abstract][Full Text] [Related]
18. [Hematopoietic stem cell transplantation in multiple myeloma].
Vela-Ojeda J; Ruiz-Esparza MA
Rev Invest Clin; 2005; 57(2):305-13. PubMed ID: 16524072
[TBL] [Abstract][Full Text] [Related]
19. Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma.
Brinker BT; Waller EK; Leong T; Heffner LT; Redei I; Langston AA; Lonial S
Cancer; 2006 May; 106(10):2171-80. PubMed ID: 16598756
[TBL] [Abstract][Full Text] [Related]
20. Management of newly diagnosed myeloma.
Rajkumar SV; Palumbo A
Hematol Oncol Clin North Am; 2007 Dec; 21(6):1141-56, ix-x. PubMed ID: 17996592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]